4.81
1.69%
+0.08
Champions Oncology Inc stock is currently priced at $4.81, with a 24-hour trading volume of 170.
It has seen a +1.69% increased in the last 24 hours and a -4.37% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.75 pivot point. If it approaches the $4.85 resistance level, significant changes may occur.
Previous Close:
$4.73
Open:
$4.67
24h Volume:
170
Market Cap:
$64.30M
Revenue:
$49.98M
Net Income/Loss:
$-9.64M
P/E Ratio:
-8.5709
EPS:
-0.5612
Net Cash Flow:
$-4.86M
1W Performance:
-0.41%
1M Performance:
-4.37%
6M Performance:
-12.07%
1Y Performance:
+5.48%
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
201 808 8400
Address
One University Plaza, Suite 307, Hackensack, NJ
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Shine On
Yahoo Canada Shine On
Champions Gala Raises Money for Lehigh Valley Topper Cancer Institute - The Valley Ledger
The Valley Ledger
Champions Gala Raises Money for Lehigh Valley Topper Cancer Institute - The Valley Ledger
The Valley Ledger
Champions Gala Raises Money for Lehigh Valley Topper Cancer Institute - LVHN News
LVHN News
How To Trade (CSBR) - Stock Traders Daily
Stock Traders Daily
Cancer Mouse Models Market [Top Trends] | The Jackson Laboratory, Taconic Biosciences, Charles River Laboratories - Motions Online
Motions Online
Champions Oncology Inc Stock (CSBR) Financials Data
Champions Oncology Inc (CSBR) Revenue 2024
CSBR reported a revenue (TTM) of $49.98 million for the quarter ending October 31, 2023, a -7.61% decline year-over-year.
Champions Oncology Inc (CSBR) Net Income 2024
CSBR net income (TTM) was -$9.64 million for the quarter ending October 31, 2023, a -9,023% decrease year-over-year.
Champions Oncology Inc (CSBR) Cash Flow 2024
CSBR recorded a free cash flow (TTM) of -$4.86 million for the quarter ending October 31, 2023, a -182.66% decrease year-over-year.
Champions Oncology Inc (CSBR) Earnings per Share 2024
CSBR earnings per share (TTM) was -$0.71 for the quarter ending October 31, 2023, a -59,067% decline year-over-year.
Champions Oncology Inc Stock (CSBR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mendelson Daniel Newman | Director |
Jan 11 '24 |
Buy |
6.27 |
2,000 |
12,540 |
197,625 |
Mendelson Daniel Newman | Director |
Jan 10 '24 |
Buy |
6.31 |
2,944 |
18,577 |
195,625 |
Mendelson Daniel Newman | Director |
Jan 09 '24 |
Buy |
6.25 |
3,000 |
18,750 |
192,681 |
Mendelson Daniel Newman | Director |
Jan 08 '24 |
Buy |
6.15 |
1,000 |
6,150 |
189,681 |
Mendelson Daniel Newman | Director |
Jan 05 '24 |
Buy |
6.09 |
2,000 |
12,180 |
188,681 |
Mendelson Daniel Newman | Director |
Jan 04 '24 |
Buy |
6.12 |
3,000 |
18,360 |
186,681 |
Mendelson Daniel Newman | Director |
Jan 03 '24 |
Buy |
5.83 |
500 |
2,915 |
183,681 |
Mendelson Daniel Newman | Director |
Dec 21 '23 |
Buy |
4.92 |
2,500 |
12,300 |
183,181 |
Mendelson Daniel Newman | Director |
Dec 20 '23 |
Buy |
4.82 |
2,100 |
10,122 |
180,681 |
Mendelson Daniel Newman | Director |
Dec 19 '23 |
Buy |
4.75 |
5,000 |
23,750 |
178,581 |
About Champions Oncology Inc
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Cap:
|
Volume (24h):